Literature DB >> 23409698

Biomarkers track damage after graded injury severity in a rat model of penetrating brain injury.

J Susie Zoltewicz1, Stefania Mondello, Boxuan Yang, Kimberly J Newsom, Firas Kobeissy, Changping Yao, Xi-Chun May Lu, Jitendra R Dave, Deborah A Shear, Kara Schmid, Virginia Rivera, Terri Cram, Jixiang Seaney, Zhiqun Zhang, Kevin K W Wang, Ronald L Hayes, Frank C Tortella.   

Abstract

The goal of this project was to determine whether biochemical markers of brain damage can be used to diagnose and assess the severity of injury in a rat model of penetrating ballistic-like brain injury (PBBI). To determine the relationship between injury magnitude and biomarker levels, rats underwent three discrete PBBI severity levels defined by the magnitude of the ballistic component of the injury, calibrated to equal 5%, 10%, or 12.5% of total rat brain volume. Cortex, cerebrospinal fluid (CSF), and blood were collected at multiple time points. Levels of three biomarkers (αII-spectrin breakdown product [SBDP150], glial fibrillary acidic protein [GFAP], and ubiquitin C-terminal hydrolase-L1 [UCH-L1]), were measured using quantitative immunoblotting and/or enzyme-linked immunosorbent assays. In injured cortex, SBDP150 and GFAP levels were increased significantly over controls. Cortical SBDP150 was elevated at 1 day but not 7 days, and GFAP at 7 days but not 1 day. At their respective time points, mean levels of SBDP150 and GFAP biomarkers in the cortex rose stepwise as injury magnitude increased. In the CSF, increasing severity of PBBI was associated with increasing concentrations of both neuronal and glial biomarkers acutely at 1 day after injury, but no trends were observed at 7 days. In plasma, SBDP150 was elevated at 5 min after 10% PBBI and at 6 h after 12.5% PBBI. UCH-L1 levels in plasma were elevated acutely at 5 min post-injury reflecting injury severity and rapidly decreased within 2 h. Overall, our results support the conclusion that biomarkers are effective indicators of brain damage after PBBI and may also aid in the assessment of injury magnitude.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23409698     DOI: 10.1089/neu.2012.2762

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  24 in total

Review 1.  Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker.

Authors:  Zhihui Yang; Kevin K W Wang
Journal:  Trends Neurosci       Date:  2015-05-11       Impact factor: 13.837

2.  Protein Biomarkers and Neuroproteomics Characterization of Microvesicles/Exosomes from Human Cerebrospinal Fluid Following Traumatic Brain Injury.

Authors:  Rachna Manek; Ahmed Moghieb; Zhihui Yang; Dhwani Kumar; Firas Kobessiy; George Anis Sarkis; Vijaya Raghavan; Kevin K W Wang
Journal:  Mol Neurobiol       Date:  2017-11-29       Impact factor: 5.590

3.  New astroglial injury-defined biomarkers for neurotrauma assessment.

Authors:  Julia Halford; Sean Shen; Kyohei Itamura; Jaclynn Levine; Albert C Chong; Gregg Czerwieniec; Thomas C Glenn; David A Hovda; Paul Vespa; Ross Bullock; W Dalton Dietrich; Stefania Mondello; Joseph A Loo; Ina-Beate Wanner
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-17       Impact factor: 6.200

Review 4.  Evidence to support mitochondrial neuroprotection, in severe traumatic brain injury.

Authors:  Shyam Gajavelli; Vishal K Sinha; Anna T Mazzeo; Markus S Spurlock; Stephanie W Lee; Aminul I Ahmed; Shoji Yokobori; Ross M Bullock
Journal:  J Bioenerg Biomembr       Date:  2014-10-31       Impact factor: 2.945

5.  Generation and Release of Neurogranin, Vimentin, and MBP Proteolytic Peptides, Following Traumatic Brain Injury.

Authors:  George Anis Sarkis; Nicholas Lees-Gayed; Joseph Banoub; Susan E Abbatielo; Claudia Robertson; William E Haskins; Richard A Yost; Kevin K W Wang
Journal:  Mol Neurobiol       Date:  2021-11-11       Impact factor: 5.590

6.  Characterization and standardization of multiassay platforms for four commonly studied traumatic brain injury protein biomarkers: a TBI Endpoints Development Study.

Authors:  George Anis Sarkis; Tian Zhu; Zhihui Yang; Xue Li; Yuan Shi; Richard Rubenstein; Richard A Yost; Geoffrey T Manley; Kevin K Wang
Journal:  Biomark Med       Date:  2021-10-22       Impact factor: 2.851

7.  Examining the Neural and Astroglial Protective Effects of Cellular Prion Protein Expression and Cell Death Protease Inhibition in Mouse Cerebrocortical Mixed Cultures.

Authors:  Kevin K W Wang; Zhihui Yang; Allen Chiu; Fan Lin; Richard Rubenstein
Journal:  Mol Neurobiol       Date:  2015-09-04       Impact factor: 5.590

8.  Initial biological qualification of SBDP-145 as a biomarker of compound-induced neurodegeneration in the rat.

Authors:  Michael L Pritt; D Greg Hall; William H Jordan; Darryl W Ballard; Kevin K W Wang; Uwe R Müller; David E Watson
Journal:  Toxicol Sci       Date:  2014-07-11       Impact factor: 4.849

9.  Plasma Anti-Glial Fibrillary Acidic Protein Autoantibody Levels during the Acute and Chronic Phases of Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study.

Authors:  Kevin K W Wang; Zhihui Yang; John K Yue; Zhiqun Zhang; Ethan A Winkler; Ava M Puccio; Ramon Diaz-Arrastia; Hester F Lingsma; Esther L Yuh; Pratik Mukherjee; Alex B Valadka; Wayne A Gordon; David O Okonkwo; Geoffrey T Manley; Shelly R Cooper; Kristen Dams-O'Connor; Allison J Hricik; Tomoo Inoue; Andrew I R Maas; David K Menon; David M Schnyer; Tuhin K Sinha; Mary J Vassar
Journal:  J Neurotrauma       Date:  2016-02-01       Impact factor: 5.269

10.  Glibenclamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.

Authors:  Ruchira M Jha; Stefania Mondello; Helen M Bramlett; C Edward Dixon; Deborah A Shear; W Dalton Dietrich; Kevin K W Wang; Zhihui Yang; Ronald L Hayes; Samuel M Poloyac; Philip E Empey; Audrey D Lafrenaye; Hong Q Yan; Shaun W Carlson; John T Povlishock; Janice S Gilsdorf; Patrick M Kochanek
Journal:  J Neurotrauma       Date:  2020-12-18       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.